Tokyo, Dec. 2 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059928) titled 'TECENTRIQ Drug Use Surveillance (ENKL)' on Dec. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Chugai Pharmaceutical Co. Ltd
Condition:
Condition - ENKL
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The following items should be confirmed under the actual conditions of the use of Tecentriq intravenous infusion (hereinafter referred to as this drug) for patients with relapsed or refractory extranodal NK/T-cell lymphoma and nasal type (ENKL) aged 12 to 18 years (hereinafter referred to as children)
Primary objective: Calculation of response rate bas...